Glenn Garmont | Investor relations |
Raj Kannan | Chief Executive Officer |
Bill Ludlam | Senior Vice President-Clinical Development and Medical Affairs |
Mark Fitzpatrick | President |
Yasmeen Rahimi | Roth Capital Partners |
Brandon Folkes | Cantor Fitzgerald |
Douglas Tsao | H.C. Wainwright |
Deepankar Roy | Brookline Capital Markets |
Good afternoon, ladies and gentlemen, and welcome to the Conference Call to discuss Chiasma's Second Quarter 2019 Operating and Financial Results. All lines are in a listen-only mode.
Thank you, operator. Please turn to Slide 1. Today, we will be making certain forward-looking statements about events and circumstances, including, but not limited to, statements regarding our development and potential commercialization of Mycapssa, our expectations on timing of release of clinical data and regulatory submissions and review periods, our plans to seek regulatory approval in the United States and European Union, our anticipated cash runway and the size and composition of potential markets for Mycapssa, if approved.